The ever-changing landscape of drug-induced injury of the lower gastrointestinal tract

Archives of Pathology and Laboratory Medicine

Volumn 140, Issue 8, 2016, Pages 748-758

  Marginean, Esmeralda Celia ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

CHEMICALLY INDUCED; COLON; CONSTIPATION; DIARRHEA; DRUG EFFECTS; GASTROINTESTINAL DISEASE; HUMAN; INTESTINE MUCOSA; LOWER GASTROINTESTINAL TRACT; NAUSEA; PATHOLOGY; VOMITING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLON; CONSTIPATION; DIARRHEA; GASTROINTESTINAL DISEASES; HUMANS; INTESTINAL MUCOSA; LOWER GASTROINTESTINAL TRACT; NAUSEA; VOMITING;

EID: 84980396077     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2015-0451-RA     Document Type: Conference Paper

References (48)

1. Goldstein JL, Cryer B. Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies. Drug Healthc Patient Saf. 2015;7:31-41.
2. De Petris G, Caldero SG, Chen L, et al. Histopathological changes in the gastrointestinal tract due to medications: an update for the surgical pathologist (part II of II). Int J Surg Pathol. 2014;22(3):202-211.
3. Nagar AB. Isolated colonic ulcers: diagnosis and management. Curr Gastroenterol Rep. 2007;9(5):422-428.
4. Lang J, Price AB, Levi AJ, Burke M, Gumpel JM, Bjarnason I. Diaphragm disease: pathology of disease of the small intestine induced by non-steroidal antiinflammatory drugs. J Clin Pathol. 1988;41(5):516-526.
5. Munipalle PC, Garud T, Light D. Diaphragmatic disease of the colon: systematic review. Colorectal Dis. 2013;15(9):1063-1069.
6. Tsukada T, Nakano T, Miyata T, Sasaki S. Life-threatening gastrointestinal mucosal necrosis during methotrexate treatment for rheumatoid arthritis. Case Rep Gastroenterol. 2013;7(3):470-475.
7. Osunkwo I, Bessmertny O, Harrison L, et al. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients. Biol Blood Marrow Transplant. 2004;10(4):246-258.
8. Star KV, Ho VT, Wang HH, Odze RD. Histologic features in colon biopsies can discriminate mycophenolate from GVHD-induced colitis. Am J Surg Pathol. 2013;37(9):1319-1328.
9. Lampert IA, Thorpe P, van Noorden S, et al. Selective sparing of enterochromaffin cells in graft versus host disease affecting the colonic mucosa. Histopathology. 1985;9(8):875-886.
10. Smith FO, Goff SL, Klapper JA, et al. Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody. J Immunother. 2007;30(1):130.
11. Soldini D, Gaspert A, Montani M, et al. Apoptotic enteropathy caused by antimetabolites and TNF-alpha antagonists. J Clin Pathol. 2014;67(7):582-586.
12. Louie CY, DiMaio MA, Matsukuma KE, Coutre SE, Berry GJ, Longacre TA. Idelalisib-associated enterocolitis: clinicopathologic features and distinction from other enterocolitides. Am J Surg Pathol. 2015;39(12):1653-1660.
13. Weidner AS, Panarelli NC, Geyer JT, et al. Idelalisib-associated colitis: histologic findings in 14 patients. Am J Surg Pathol. 2015;39(12):1661-1667.
14. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006;24(15):2283-2289.
15. El Fassi D, Nielsen CH, Kjeldsen J, Clemmensen O, Hegedus L. Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease. Gut. 2008;57(5):714-715.
16. Kutsch E, Kreiger P, Consolini D, Furuya KN. Colonic perforation after rituximab treatment for posttransplant lymphoproliferative disorder. J Pediatr Gastroenterol Nutr. 2013;56(6):e41.
17. Cappell MS. Colonic toxicity of administered drugs and chemicals. Am J Gastroenterol. 2004;99(6):1175-1190.
18. Frossard JL, Spahr L, Queneau PE, Armenian B, Brundler MA, Hadengue A. Ischemic colitis during pregnancy and contraceptive medication. Digestion. 2001;64(2):125-127.
19. Linder JD, Monkemuller KE, Raijman I, Johnson L, Lazenby AJ, Wilcox CM. Cocaine-associated ischemic colitis. South Med J. 2000;93(9):909-913.
20. Ruiz-Tovar J, Candela F, Oliver I, Calpena R. Sigmoid colon stenosis: a long-term sequelae of cocaine-induced ischemic colitis. Am Surg. 2010;76(9): E178-E179.
21. Rodman RE, Willson TD, Connolly MM, Podbielski FJ. Ischemic colitis secondary to ergotamine use: a case study. Case Rep Gastroenterol. 2011;5(1):1-4.
22. Nguyen TQ, Lewis JH. Sumatriptan-associated ischemic colitis: case report and review of the literature and FAERS. Drug Saf. 2014;37(2):109-121.
23. Harel Z, Harel S, Shah PS, Wald R, Perl J, Bell CM. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am J Med. 2013;126(3):264.e29-24.
24. Joo M, Bae WK, Kim NH, Han SR. Colonic mucosal necrosis following administration of calcium polystryrene sulfonate (Kalimate) in a uremic patient. J Korean Med Sci. 2009;24(6):1207-1211.
25. Arnold MA, Swanson BJ, Crowder CD, et al. Colesevelam and colestipol: novel medication resins in the gastrointestinal tract. Am J Surg Pathol. 2014; 38(11):1530-1537.
26. Swanson BJ, Limketkai BN, Liu TC, et al. Sevelamer crystals in the gastrointestinal tract (GIT): a new entity associated with mucosal injury. Am J Surg Pathol. 2013;37(11):1686-1693.
27. Stein BL, Lamoureux E, Miller M, Vasilevsky CA, Julien L, Gordon PH. Glutaraldehyde-induced colitis. Can J Surg. 2001;44(2):113-116.
28. Selbst MK, Ahrens WA, Robert ME, Friedman A, Proctor DD, Jain D. Spectrum of histologic changes in colonic biopsies in patients treated with mycophenolate mofetil. Mod Pathol. 2009;22(6):737-743.
29. Liapis G, Boletis J, Skalioti C, et al. Histological spectrum of mycophenolate mofetil-related colitis: association with apoptosis. Histopathology. 2013; 63(5):649-658.
30. Goldstein NS, Cinenza AN. The histopathology of nonsteroidal antiinflammatory drug-associated colitis. Am J Clin Pathol. 1998;110(5):622-628.
31. Driman DK, Preiksaitis HG. Colorectal inflammation and increased cell proliferation associated with oral sodium phosphate bowel preparation solution. Hum pathol. Sep 1998;29(9):972-978.
32. Volk EE, Shapiro BD, Easley KA, Goldblum JR. The clinical significance of a biopsy-based diagnosis of focal active colitis: a clinicopathologic study of 31 cases. Mod Pathol. 1998;11(8):789-794.
33. Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. 2005;12(12):1005-1016.
34. Oble DA, Mino-Kenudson M, Goldsmith J, et al. Alpha-CTLA-4 mAbassociated panenteritis: a histologic and immunohistochemical analysis. Am J Surg Pathol. 2008;32(8):1130-1137.
35. Thomson RD, Lestina LS, Bensen SP, Toor A, Maheshwari Y, Ratcliffe NR. Lansoprazole-associated microscopic colitis: a case series. Am J Gastroenterol. 2002;97(11):2908-2913.
36. Thiolet C, Bredin C, Rimlinger H, Nizou C, Mennecier D, Farret O. Lymphocytic colitis following administration of Cyclo 3 fort [in French]. Presse Med. Sep 6 2003;32(28):1323-1324.
37. Davila M. Neutropenic enterocolitis: current issues in diagnosis and management. Curr Infect Dis Rep. 2007;9(2):116-120.
38. Kasturi KS, Mummadi RR, Sood GK. Neutropenic enterocolitis: an unusual complication of HCV combination therapy with PEG-IFN and ribavirin. Eur J Intern Med. 2008;19(5):372-373.
39. Kim JH, Jang JW, You CR, You SY, Jung MK, Jung JH. Fatal neutropenic enterocolitis during pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection. Gut Liver. 2009;3(3):218-221.
40. Sachak T, Arnold MA, Naini BV, et al. Neutropenic enterocolitis: new insights into a deadly entity. Am J Surg Pathol. 2015;39(12):1635-1642.
41. Mpofu S, Mpofu CM, Hutchinson D, Maier AE, Dodd SR, Moots RJ. Steroids, non-steroidal anti-inflammatory drugs, and sigmoid diverticular abscess perforation in rheumatic conditions. Ann Rheum Dis. 2004;63(5):588-590.
42. Piekarek K, Israelsson LA. Perforated colonic diverticular disease: the importance of NSAIDs, opioids, corticosteroids, and calcium channel blockers. Int J Colorectal Dis. 2008;23(12):1193-1197.
43. Guinaudeau E, Person B, Valo I, Tuech JJ, Rousselet MC. Colonic malacoplakia and ulcerative colitis: report of a case. Gastroenterol Clin Biol. 2002;26(2):174-177.
44. Kim PT, Davis JE, Erb SR, Yoshida EM, Steinbrecher UP. Colonic malakoplakia in a liver transplant recipient. Can J Gastroenterol. 2007;21(11): 753-755.
45. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005;294(23):2989-2995.
46. Tzardi M, Papadakis M, Giannikaki E, Datseri G, Kouroumalis EA, Kalogeraki A. Pseudomembranous colitis with presence of signet-ring cells: report of two cases and review of the literature. Ann Gastroenterol. 2011;24(3): 222-224.
47. Cameselle-Teijeiro J, Abdulkader I, Forteza J. Signet-ring cell change in pseudomembranous colitis versus signet-ring cell carcinoma. Am J Surg Pathol. 2004;28(8):1111.
48. Daniels JA, Gibson MK, Xu L, et al. Gastrointestinal tract epithelial changes associated with taxanes: marker of drug toxicity versus effect. Am J Surg Pathol. 2008;32(3):473-477.